CDK12 Gene Alterations in Prostate Cancer: Present but Clinically Actionable?

被引：2
|
作者：
Marciscano, Ariel E. [1 ]
Barbieri, Christopher E. [2 ,3 ]
机构：
[1] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY USA
[2] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[3] Weill Cornell Med Coll, Sandra & Edward Meyer Canc Ctr, New York, NY USA
来源：
EUROPEAN UROLOGY | 2020年 / 78卷 / 05期
关键词：
DNA-REPAIR;
D O I：
10.1016/j.eururo.2020.04.007
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：680 / 681
页数：2
相关论文
共 50 条
  • [1] CDK12 Changes Telling in Prostate Cancer
    Caruso, Catherine
    CANCER DISCOVERY, 2018, 8 (09) : 1055 - 1056
  • [2] CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer
    Lotan, Tamara L.
    Antonarakis, Emmanuel S.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 380 - 382
  • [3] Analysis of CDK12 alterations in a pan-cancer database
    Pan, Elizabeth
    Cabal, Angelo
    Javier-DesLoges, Juan
    Patel, Devin
    Panian, Justine
    Lee, Suzanna
    Shaya, Justin
    Nonato, Taylor
    Xu, Xiaojun
    Stewart, Tyler
    Rose, Brent
    Shabaik, Ahmed
    Cohen, Ezra
    Kurzrock, Razelle
    Tamayo, Pablo
    McKay, Rana R.
    CANCER MEDICINE, 2022, 11 (03): : 753 - 763
  • [4] Lack of evidence for CDK12 as an ovarian cancer predisposing gene
    Eeckhoutte, Alexandre
    Saint-Ghislain, Mathilde
    Reverdy, Manon
    Raynal, Virginie
    Baulande, Sylvain
    Bataillon, Guillaume
    Golmard, Lisa
    Stoppa-Lyonnet, Dominique
    Popova, Tatiana
    Houdayer, Claude
    Manie, Elodie
    Stern, Marc-Henri
    FAMILIAL CANCER, 2020, 19 (03) : 203 - 209
  • [5] Lack of evidence for CDK12 as an ovarian cancer predisposing gene
    Alexandre Eeckhoutte
    Mathilde Saint-Ghislain
    Manon Reverdy
    Virginie Raynal
    Sylvain Baulande
    Guillaume Bataillon
    Lisa Golmard
    Dominique Stoppa-Lyonnet
    Tatiana Popova
    Claude Houdayer
    Elodie Manié
    Marc-Henri Stern
    Familial Cancer, 2020, 19 : 203 - 209
  • [6] CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
    Wang, Xiao
    Chen, Hong
    Luo, Jun
    Xie, Liping
    EUROPEAN UROLOGY, 2020, 77 (03) : 342 - 343
  • [7] CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
    Lei, Hanqi
    Wang, Zifeng
    Jiang, Donggen
    Liu, Fang
    Liu, Meiling
    Lei, Xinxing
    Yang, Yafei
    He, Bin
    Yan, Min
    Huang, Hai
    Liu, Quentin
    Pang, Jun
    CELL DEATH & DISEASE, 2021, 12 (08)
  • [8] CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
    Hanqi Lei
    Zifeng Wang
    Donggen Jiang
    Fang Liu
    Meiling Liu
    Xinxing Lei
    Yafei Yang
    Bin He
    Min Yan
    Hai Huang
    Quentin Liu
    Jun Pang
    Cell Death & Disease, 12
  • [9] Biallelic alterations in BRCA2, ATM, or CDK12 in metastatic prostate cancer via circulating tumor DNA
    Warner, Evan
    Yip, Steven
    Annala, Matti
    Murtha, Andrew
    Herberts, Cameron
    Chi, Kim
    Wyatt, Alexander
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
    Wu, Yi-Mi
    Cieslik, Marcin
    Lonigro, Robert J.
    Vats, Pankaj
    Reimers, Melissa A.
    Cao, Xuhong
    Ning, Yu
    Wang, Lisha
    Kunju, Lakshmi P.
    de Sarkar, Navonil
    Heath, Elisabeth I.
    Chou, Jonathan
    Feng, Felix Y.
    Nelson, Peter S.
    de Bono, Johann S.
    Zou, Weiping
    Montgomery, Bruce
    Alva, Ajjai
    Robinson, Dan R.
    Chinnaiyan, Arul M.
    CELL, 2018, 173 (07) : 1770 - +
12345